(Q38543407)

4 September 2017

1 reference

title

Genomic alterations in lung adenocarcinoma (English)

1 reference

4 September 2017

1 reference

Siddhartha Devarakonda

series ordinal

1

1 reference

4 September 2017

Daniel Morgensztern

series ordinal

2

1 reference

4 September 2017

Ramaswamy Govindan

series ordinal

3

1 reference

4 September 2017

publication date

1 July 2015

1 reference

Lancet Oncology Commission

4 September 2017

published in

1 reference

4 September 2017

volume

16

1 reference

4 September 2017

issue

7

1 reference

4 September 2017

page(s)

e342-51

1 reference

4 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Pathology of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Big science: The cancer genome challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Comprehensive genomic characterization of squamous cell lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Comprehensive molecular profiling of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Pan-cancer patterns of somatic copy number alteration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

The landscape of somatic copy-number alteration across human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Characterizing the cancer genome in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Inhibition of distal lung morphogenesis in Nkx2.1(-/-) embryos

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Preparing for the first breath: genetic and cellular mechanisms in lung development

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Reflecting on 25 years with MYC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Analysis of genomic targets reveals complex functions of MYC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

The MAX-interacting transcription factor network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

A small-cell lung cancer genome with complex signatures of tobacco exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Mutational landscape and significance across 12 major cancer types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

A landscape of driver mutations in melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Mutational heterogeneity in cancer and the search for new cancer-associated genes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Lung cancer in never smokers: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

The Ras superfamily at a glance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

RAS oncogenes: weaving a tumorigenic web

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Acquired resistance to TKIs in solid tumours: learning from lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

The transcriptional landscape and mutational profile of lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

New driver mutations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Oncogenic RIT1 mutations in lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Discovery and saturation analysis of cancer genes across 21 tumour types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Novel targets in non-small cell lung cancer: ROS1 and RET fusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Misregulation of pre-mRNA alternative splicing in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Gene expression profiling predicts clinical outcome of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Impact of biomarkers on clinical trial risk in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Cancer epigenetics: from mechanism to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Exploring the utility of human DNA methylation arrays for profiling mouse genomic DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Evolution of the cancer genome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

A small-molecule inducer of the antioxidant response element

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Identification of retinoic acid as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

Clinical next-generation sequencing in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2900077-7

7 January 2021

10.1016/S1470-2045(15)00077-7

Identifiers

DOI

1 reference

release_xve7752yvvft3dbk4pmrvcxvg4

4 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xve7752yvvft3dbk4pmrvcxvg4

24 November 2022

mapped directly with Wikidata item

1 reference